Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Getinge ( ($SE:GETI.B) ) has issued an update.
Getinge has announced that the EU CE Mark for its Cardiosave Intra-Aortic Balloon Pump has been reinstated by the EU Notified Body TÜV SÜD after addressing compliance gaps and implementing design improvements. This reinstatement allows Getinge to resume deliveries of the device to markets accepting the CE mark, ensuring healthcare professionals and patients have access to this critical cardiac care device.
The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK180.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.
More about Getinge
Getinge is a company that provides hospitals and life science institutions with products and solutions designed to improve clinical results and optimize workflows. Their offerings include products for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life sciences. The company employs approximately 12,000 people worldwide and sells its products in over 135 countries.
YTD Price Performance: 7.06%
Average Trading Volume: 665,539
Technical Sentiment Signal: Sell
Current Market Cap: SEK51.61B
For detailed information about GETI.B stock, go to TipRanks’ Stock Analysis page.